Novo Nordisk has launched the Wegovy pill in the United Arab Emirates, marking the first availability outside the US. The pill, containing semaglutide, is approved to reduce excess body weight by an average of 17% and lower the risk of major cardiovascular events in adults with obesity and related heart conditions. This launch expands access to innovative obesity treatments in a region where 28% of adults are obese. Novo Nordisk plans to introduce the pill in more countries later in 2026, supporting long-term obesity management globally.
Novo Nordisk's oral GLP-1 weight-loss drug, Wegovy pill, continues to outsell Eli Lilly's competing tablet, Foundayo, with around 146,000 prescriptions in the week ending May 22. However, weekly prescription growth has slowed to 2% as the market adju...
Novo Nordisk began a share repurchase program on 6 May 2026, aiming to buy back up to DKK 15 billion worth of B shares over 12 months starting 4 February 2026. As of 29 May 2026, the company repurchased 17.9 million shares at an average price of DKK ...
